Tyra Biosciences, Inc. (NASDAQ:TYRA) Shares Sold by Auour Investments LLC

Auour Investments LLC lessened its position in shares of Tyra Biosciences, Inc. (NASDAQ:TYRA - Free Report) by 75.3% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 21,020 shares of the company's stock after selling 64,000 shares during the quarter. Auour Investments LLC's holdings in Tyra Biosciences were worth $494,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. RA Capital Management L.P. increased its holdings in Tyra Biosciences by 43.9% in the 1st quarter. RA Capital Management L.P. now owns 10,416,609 shares of the company's stock valued at $170,832,000 after purchasing an additional 3,180,155 shares during the last quarter. BVF Inc. IL grew its stake in shares of Tyra Biosciences by 70.1% in the first quarter. BVF Inc. IL now owns 4,661,194 shares of the company's stock worth $76,444,000 after acquiring an additional 1,921,599 shares in the last quarter. Perceptive Advisors LLC grew its stake in shares of Tyra Biosciences by 50.5% in the second quarter. Perceptive Advisors LLC now owns 1,007,367 shares of the company's stock worth $16,108,000 after acquiring an additional 338,208 shares in the last quarter. Vanguard Group Inc. grew its stake in shares of Tyra Biosciences by 18.6% in the first quarter. Vanguard Group Inc. now owns 899,800 shares of the company's stock worth $14,757,000 after acquiring an additional 140,833 shares in the last quarter. Finally, Kynam Capital Management LP grew its stake in shares of Tyra Biosciences by 51.4% in the first quarter. Kynam Capital Management LP now owns 515,190 shares of the company's stock worth $8,449,000 after acquiring an additional 175,000 shares in the last quarter. Hedge funds and other institutional investors own 84.14% of the company's stock.

Tyra Biosciences Trading Up 2.1 %

Shares of TYRA stock traded up $0.34 on Tuesday, reaching $16.76. 295,074 shares of the stock were exchanged, compared to its average volume of 187,795. Tyra Biosciences, Inc. has a twelve month low of $10.60 and a twelve month high of $29.60. The company has a market capitalization of $885.10 million, a price-to-earnings ratio of -9.72 and a beta of 1.08. The business's 50 day moving average price is $22.28 and its 200 day moving average price is $19.97.

Tyra Biosciences (NASDAQ:TYRA - Get Free Report) last announced its quarterly earnings results on Wednesday, August 7th. The company reported ($0.32) earnings per share for the quarter, beating analysts' consensus estimates of ($0.41) by $0.09. Equities research analysts forecast that Tyra Biosciences, Inc. will post -1.53 earnings per share for the current year.

Insider Activity at Tyra Biosciences

In related news, CFO Alan Fuhrman purchased 9,500 shares of Tyra Biosciences stock in a transaction that occurred on Wednesday, October 30th. The stock was purchased at an average cost of $16.00 per share, with a total value of $152,000.00. Following the completion of the transaction, the chief financial officer now directly owns 12,849 shares in the company, valued at approximately $205,584. The trade was a 200.00 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, Director Nina S. Kjellson sold 11,078 shares of the company's stock in a transaction dated Wednesday, October 30th. The shares were sold at an average price of $16.17, for a total value of $179,131.26. Following the completion of the sale, the director now directly owns 472,207 shares of the company's stock, valued at approximately $7,635,587.19. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Alan Fuhrman bought 9,500 shares of Tyra Biosciences stock in a transaction dated Wednesday, October 30th. The stock was acquired at an average cost of $16.00 per share, with a total value of $152,000.00. Following the completion of the acquisition, the chief financial officer now directly owns 12,849 shares of the company's stock, valued at approximately $205,584. The trade was a 200.00 % increase in their position. The disclosure for this purchase can be found here. Insiders sold a total of 99,974 shares of company stock valued at $2,217,189 over the last ninety days. Insiders own 15.40% of the company's stock.

Analyst Ratings Changes

Several equities analysts have commented on TYRA shares. Wedbush restated an "outperform" rating and issued a $28.00 price target on shares of Tyra Biosciences in a research note on Friday, October 25th. Oppenheimer boosted their price target on shares of Tyra Biosciences from $25.00 to $33.00 and gave the stock an "outperform" rating in a research note on Thursday, September 19th. HC Wainwright boosted their price target on shares of Tyra Biosciences from $30.00 to $32.00 and gave the stock a "buy" rating in a research note on Monday, October 28th. Piper Sandler initiated coverage on shares of Tyra Biosciences in a research note on Thursday, August 15th. They set an "overweight" rating and a $33.00 target price for the company. Finally, Bank of America upgraded shares of Tyra Biosciences from a "neutral" rating to a "buy" rating and boosted their target price for the stock from $22.00 to $31.00 in a research note on Friday, October 18th. Five analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus target price of $31.40.

Tyra Biosciences Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.